Lisata Therapeutics Inc
Veridion Score
Composite trend over time
Why is LSTA moving today?
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LSTA.
Continue the LSTA research trail.
LSTA insider activity
Lisata Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$122K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-13 | 2026-01-09 | Imam Tariq | Insider | sell | $1.97 | 513 | 36,078 | $1K | SEC Form 4 |
| 2026-01-13 | 2026-01-09 | Imam Tariq | Insider | sell | $1.97 | 747 | 36,591 | $1K | SEC Form 4 |
| 2026-01-13 | 2026-01-09 | Imam Tariq | Insider | sell | $1.97 | 840 | 37,338 | $2K | SEC Form 4 |
| 2026-01-13 | 2026-01-09 | Imam Tariq | Insider | sell | $1.97 | 1,401 | 38,178 | $3K | SEC Form 4 |
| 2026-01-13 | 2026-01-09 | Nisco James | Insider | sell | $1.97 | 781 | 32,311 | $2K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 11 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moLSTA contract awards, year to date.
Public federal awards linked to this ticker.
LSTA lobbying filings, year to date.
Registered lobbying filings matched to Lisata Therapeutics Inc.